Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Average Sales Prices Expected To Increase 3.4% From Proposed Rule

Executive Summary

The Centers for Medicare & Medicaid Services expects that first quarter 2005 reimbursement rates for Medicare Part B drugs will reflect an increase of about 3.4% from those published in its proposed rule

You may also be interested in...



CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%

Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B

CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%

Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B

Procrit, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says

Medicare reimbursement rates for 2005 will not cover costs of Johnson & Johnson's Procrit (epoetin) for the majority of oncology practices, according to the American Society of Clinical Oncology

Related Content

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel